Leaflet FEIBA 25U / ml powder and solvent for solution for infusion

Indicated for: bleeding in hemophilia with inhibitors

Route of administration: infusion

Substance: coagulation anti-inhibitor complex (coagulation factor)

ATC: B02BD03 (Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors)

The coagulation anti-inhibitor complex is used for the treatment of bleeding episodes in patients with hemophilia A or B who have inhibitors to coagulation factors VIII or IX. It works by providing coagulation factors that bypass the inhibitors, promoting blood clot formation.

The medication is administered intravenously, as directed by a doctor, usually during bleeding episodes or before surgical procedures. It is important for patients to follow the recommended dosage and be monitored for treatment effectiveness.

Patients should be aware of potential side effects, such as allergic reactions, fever, or thrombosis. It is important to inform the doctor of any unusual symptoms.

Common side effects include injection site reactions, fever, and nausea. In rare cases, severe reactions such as thrombosis or anaphylactic reactions may occur. Patients should be informed of these risks before use.

General data about FEIBA 25U / ml

  • Substance: coagulation anti-inhibitor complex
  • Date of latest medicines list: 01-04-2026
  • Product code: W62498002
  • Concentration: 25U / ml
  • Pharmaceutical form: powder and solvent for solution for infusion
  • Quantity: 1
  • Product type: Original
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: BAXTER AG - AUSTRIA
  • Holder: BAXALTA INNOVATIONS GMBH - AUSTRIA
  • Number: 11224/2018/02
  • Shelf life: 2 years

Concentrations available for coagulation anti-inhibitor complex

  • 1000 U
  • 1000 U/20ml
  • 100U/ml
  • 25U/ml
  • 500 U/20ml
  • 500U
  • 50U/ml